## Toshihiro Nagato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1593768/publications.pdf

Version: 2024-02-01

304743 330143 1,548 73 22 citations h-index papers

g-index 73 73 73 2164 docs citations times ranked citing authors all docs

37

#	Article	IF	CITATIONS
1	Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunology, Immunotherapy, 2017, 66, 705-716.	4.2	128
2	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 877-890.	4.2	126
3	Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors. Clinical Cancer Research, 2014, 20, 1223-1234.	7.0	82
4	Expression of Interleukin-9 in Nasal Natural Killer/T-Cell Lymphoma Cell Lines and Patients. Clinical Cancer Research, 2005, 11, 8250-8257.	7.0	76
5	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress. Frontiers in Pediatrics, 2019, 7, 141.	1.9	73
6	Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. International Journal of Clinical Oncology, 2009, 14, 181-190.	2.2	66
7	Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma. Journal of Medical Virology, 2007, 79, 562-572.	<b>5.</b> O	55
8	Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/Tâ€cell lymphoma cells by cell contactâ€dependent interaction through membraneâ€bound ILâ€15. International Journal of Cancer, 2012, 130, 48-58.	5.1	50
9	Production of Interferon-γ–Inducible Protein-10 and Its Role as an Autocrine Invasion Factor in Nasal Natural Killer/T-Cell Lymphoma Cells. Clinical Cancer Research, 2009, 15, 6771-6779.	7.0	48
10	CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunology, Immunotherapy, 2015, 64, 697-705.	4.2	48
11	Downregulation of miRâ€15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/Tâ€cell lymphoma. American Journal of Hematology, 2014, 89, 25-33.	4.1	42
12	Sequence variations of Epstein–Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes, 2007, 34, 47-54.	1.6	41
13	Induction of EBV–Latent Membrane Protein 1–Specific MHC Class Il–Restricted T-Cell Responses against Natural Killer Lymphoma Cells. Cancer Research, 2008, 68, 901-908.	0.9	41
14	Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthroâ€osteitis: A retrospective subjective and objective quantitative analysis of 138 patients. Journal of Dermatology, 2018, 45, 812-823.	1.2	40
15	Circulating Epsteinâ€Barr virus–encoded microâ€RNAs as potential biomarkers for nasal natural killer/Tâ€cell lymphoma. Hematological Oncology, 2017, 35, 655-663.	1.7	39
16	Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunology, Immunotherapy, 2006, 55, 850-860.	4.2	36
17	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncolmmunology, 2016, 5, e1169356.	4.6	34
18	Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP. Clinical Cancer Research, 2005, 11, 3869-3878.	7.0	32

#	Article	IF	CITATIONS
19	The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunology, Immunotherapy, 2019, 68, 455-466.	4.2	31
20	Expression of <scp>CD</scp> 70 in nasal natural killer/ <scp>T</scp> cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble <scp>CD</scp> 27. British Journal of Haematology, 2013, 160, 331-342.	2.5	29
21	Effects of STING stimulation on macrophages: STING agonists polarize into "classically―or "alternatively―activated macrophages?. Human Vaccines and Immunotherapeutics, 2018, 14, 285-287.	3.3	29
22	A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy. Cellular Immunology, 2019, 341, 103925.	3.0	28
23	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. Journal of Experimental Medicine, 2021, 218, .	8.5	27
24	Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma. Scientific Reports, 2015, 5, 16280.	3.3	22
25	Functional Analysis of Birch Pollen Allergen Bet $\nu$ 1-Specific Regulatory T Cells. Journal of Immunology, 2007, 178, 1189-1198.	0.8	21
26	Laryngeal plexiform schwannoma as first symptom in a patient with neurofibromatosis type 2. Clinical Neurology and Neurosurgery, 2010, 112, 505-508.	1.4	19
27	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2020, 522, 408-414.	2.1	19
28	Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. OncoImmunology, 2022, 11, 2021619.	4.6	19
29	A novel combinatorial cancer immunotherapy. Oncolmmunology, 2014, 3, e28440.	4.6	17
30	Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein. Clinical Cancer Research, 2004, 10, 7053-7062.	7.0	15
31	Novel treatment for earlyâ€stage nasal natural killer/Tâ€cell lymphoma: intraâ€maxillary arterial infusion chemotherapy with concomitant radiotherapy. Hematological Oncology, 2017, 35, 158-162.	1.7	15
32	Intratumoral injection of IFN- $\hat{l}^2$ induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochemical and Biophysical Research Communications, 2017, 490, 521-527.	2.1	15
33	Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 989-999.	4.2	15
34	Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. Oncolmmunology, 2018, 7, e1466771.	4.6	14
35	Soluble ICAM-1 secretion and its functional role as an autocrine growth factor in nasal NK/T cell lymphoma cells. Experimental Hematology, 2013, 41, 711-718.	0.4	13
36	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2019, 17, 207.	4.4	13

#	Article	IF	Citations
37	Expression of placenta-specific $1$ and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncolmmunology, 2021, 10, 1856545.	4.6	13
38	Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Laboratory Investigation, 2019, 99, 612-624.	3.7	12
39	Selected Amino Acid Change Encoding Epstein-Barr Virus-Specific T Cell Epitope of the LMP2A Gene in Japanese Nasal NK/T Cell Lymphoma Patients. Intervirology, 2007, 50, 319-322.	2.8	11
40	Up-regulation of CX3CR1 on tonsillar CD8-positive cells in patients with IgA nephropathy. Human Immunology, 2017, 78, 375-383.	2.4	11
41	A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. Cancer Immunology, Immunotherapy, 2021, 70, 2301-2312.	4.2	11
42	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. Cancer Immunology, Immunotherapy, 2021, 70, 3421-3434.	4.2	11
43	Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein–Barr Virus Relation. Microorganisms, 2021, 9, 1381.	3.6	11
44	<scp>IFN</scp> â€Î±∫βâ€mediated <scp>NK2R</scp> expression is related to the malignancy of colon cancer cells. Cancer Science, 2022, , .	3.9	7
45	Congenital cholesteatoma isolated to the mastoid presenting as stricture of the external auditory canal. International Journal of Pediatric Otorhinolaryngology, 2012, 76, 754-756.	1.0	6
46	The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer. Oncology Letters, 2021, 21, 420.	1.8	6
47	A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Science, 2021, 112, 2705-2713.	3.9	6
48	Clinical images: Otitis media and nasal granulation in Wegener's granulomatosis. Arthritis and Rheumatism, 2009, 60, 379-379.	6.7	4
49	Video-assisted thyroidectomy (VANS method) for benign thyroid nodule: summary of 182 cases in a single institution. Journal of Japan Society for Head and Neck Surgery, 2017, 27, 45-52.	0.0	4
50	A tumor metastasisâ€associated molecule <scp>TWIST1</scp> is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer Science, 2022, 113, 2526-2535.	3.9	4
51	Clinical images: Eagle's syndrome. Arthritis and Rheumatism, 2012, 64, 1561-1561.	6.7	2
52	A Case of Epithelial-myoepithelial Carcinoma of Parotid Gland. Practica Otologica, 2009, 102, 1033-1037.	0.0	2
53	A Case of Papillary Carcinoma of the Thyroglossal Duct. Practica Otologica, Supplement, 2013, 137, 118-119.	0.0	1
54	Video-assisted total thyroidectomy for Graves' disease. Journal of Japan Society for Head and Neck Surgery, 2016, 26, 83-89.	0.0	1

#	Article	IF	CITATIONS
55	Subglottic Stenosis in Granulomatosis With Polyangiitis. American Journal of the Medical Sciences, 2019, 357, e13-e14.	1.1	1
56	Ulcerated Lesions of the Midline Gingiva and Soft Palate. American Journal of the Medical Sciences, 2020, 360, 77.	1.1	1
57	A Case of Facial Stab Wound with Scissors. Practica Otologica, 2009, 102, 433-436.	0.0	1
58	Thyroid Metastasis of Breast Carcinoma: A Case Report. Practica Otologica, 2009, 102, 291-295.	0.0	1
59	Four Cases of Mumps with Laryngeal Edema. Practica Otologica, 2012, 105, 277-284.	0.0	1
60	A Case of Papillary Carcinoma of the Thyroglossal Duct. Practica Otologica, 2013, 106, 447-453.	0.0	1
61	Two Cases of Optic Nerve Neuropathy from Graves' Ophthalmopathy Treated by Endoscopic Orbital Decompression. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2016, 55, 169-175.	0.0	1
62	A Case of PFAPA Syndrome. Practica Otologica, Supplement, 2013, 137, 86-87.	0.0	0
63	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. Practica Otologica, Supplement, 2013, 137, 52-53.	0.0	0
64	Helper T-cell based immunotherapy combined with adjuvants in head and neck squamous cell carcinoma. Journal of Japan Society of Immunology & Allergology in Otolaryngology, 2014, 32, 185-190.	0.0	0
65	Innovative immunotherapy for nasal NK/T-cell lymphoma. Journal of Japan Society of Immunology & Allergology in Otolaryngology, 2018, 36, 15-22.	0.0	0
66	A Case of Nasal Dermoplasty for Hereditary Hemorrhagic Telangiectasia. Practica Otologica, 2012, 105, 747-751.	0.0	0
67	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. Practica Otologica, 2013, 106, 423-429.	0.0	0
68	A Case of PFAPA Syndrome. Practica Otologica, 2013, 106, 329-333.	0.0	0
69	A Case of Adenomatoid Odontogenic Tumor of the Maxillary Sinus. Practica Otologica, 2018, 111, 483-490.	0.0	0
70	A Case of Vascular Malformation of the Hypopharynx Treated with Sclerotherapy. Practica Otologica, 2018, 111, 337-343.	0.0	0
71	Fifth Report of Hands-on Seminar on Basic Research for Clinicians at the 57 <sup>th</sup> Annual Meeting of the Japanese Rhinologic Society. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2019, 58, 152-158.	0.0	0
72	A Case of Bilateral Tonsillar Hypertrophy as the First Manifestation of Acute Leukemia. Practica Otologica, 2020, 113, 251-255.	0.0	0

 #	Article	IF	CITATIONS
73	A Case of Secretory Carcinoma of the Submandibular Gland Harboring an <i>ETV6-X</i> Fusion Gene. Practica Otologica, 2020, 113, 787-792.	0.0	0